Anne Odonnell
Pulmonary Disease · Washington, DCNPI 1629066899
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $48,481 of the $61,367 with a category attached, or 79.0%. 16 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 36.7% of the total. Reporting peaked in 2021 at $14,740 and has fallen 56.6% since, to $6,400 in 2025. Among pulmonary disease clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $818.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$23K
- Insmed, Inc.$21K
- Merck$5K
- Mannkind Corporation$5K
- Paratek Pharmaceuticals, Inc.$2K
- Electromed, Inc.$2K
- plus $3K from 10 others
Across 618 payments — averaging $2541.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$1.2M
- Paratek Pharmaceuticals, Inc.$82K
- Boehringer Ingelheim$47K
- Verona Pharma, Inc.$41K
- Mannkind Corporation$37K
- GSK$34K
- plus $121K from 6 others
What the payments were for
- Consulting fees$48,48179%
- Speaking & faculty fees$7,88913%
- Travel & lodging$1,2452%
- Food & beverage$3,6876%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 19 | $22,510 |
| Insmed, Inc. | 31 | $21,239 |
| Merck | 5 | $5,426 |
| Mannkind Corporation | 1 | $4,500 |
| Paratek Pharmaceuticals, Inc. | 3 | $2,476 |
| Electromed, Inc. | 1 | $2,150 |
| Astrazeneca UK Limited | 1 | $1,945 |
| Sanofi | 3 | $302 |
| AstraZeneca | 2 | $215 |
| Bayer | 1 | $122 |
| United Therapeutics Corporation | 1 | $110 |
| GSK | 1 | $109 |
| Mylan Specialty L.p. | 1 | $95 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $71 |
| CSL Behring | 3 | $65 |
| Zambon USA Ltd. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,367 in reported general payments places this provider in the 95th percentile of 56 pulmonary disease providers in District of Columbia.
See all pulmonary disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 11 | $140,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $117,273 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $62,494 |
| Spiriva RespimatTiotropium Bromide | 37 | $36,532 |
| Spiriva HandihalerTiotropium Bromide | 21 | $25,432 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $20,554 |
| ColistimethateColistin (Colistimethate Na) | 16 | $11,842 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,814 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,764 |
| Arnuity ElliptaFluticasone Furoate | 13 | $4,889 |
| Amikacin Sulfate | 15 | $4,529 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $4,232 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $4,167 |
| Ethambutol Hcl | 59 | $3,949 |
| Azithromycin | 86 | $3,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $109 | $205,209212 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $2,476 | $140,86611 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $215 | $22,81156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 pulmonary disease providers in District of Columbia.
Other pulmonary disease in Washington
- Andrew ShorrWashington$349K
- Eric AndersonWashington$215K
- Andrew LernerWashington$19K
- Guillermo GutierrezWashington$14K
- Khalil DiabWashington$10K
- Lorenzo LeysWashington$9K
- Rebecca KrochmalWashington$9K
- Steven LernerWashington$6K
- Karen FaganWashington$6K
- Leslie KingslowWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.